Sale of Shares By Dollarama Insiders

PR Newswire

MONTREAL, Dec. 11, 2020 /PRNewswire/ – Dollarama Inc. (TSX: DOL) (“Dollarama” or the “Corporation”) announced today that two insiders, namely GRI Investments Inc., a private corporation controlled by the Rossy family, and The Rossy Foundation, have agreed to sell respectively 875,000 and 1,625,000 common shares of Dollarama in block trades to a financial institution, representing an aggregate of 2,500,000 common shares of Dollarama.

Once the trades are settled, GRI Investments Inc. will hold 4,264,614 common shares and The Rossy Foundation will hold 7,959,723 common shares, representing, in aggregate, 12,224,337 common shares or approximately 3.9% of the Corporation’s total number of common shares issued and outstanding.

Proceeds from the sale of shares by The Rossy Foundation will be used to fund existing commitments to charitable organizations. The decision by GRI Investments Inc. to sell a portion of its holdings in Dollarama was made for financial diversification purposes. Trades are expected to close on or about December 15, 2020.

About Dollarama

Dollarama is a recognized Canadian value retailer offering a broad assortment of consumable products, general merchandise and seasonal items both in-store and online. Our 1,333 locations across Canada provide customers with compelling value in convenient locations, including metropolitan areas, mid-sized cities and small towns. Select products are also available, by the full case only, through our online store at www.dollarama.com. Our quality merchandise is sold at select, fixed price points up to $4.00.

Dollarama also owns a 50.1% interest in Dollarcity, a growing Latin American value retailer. Dollarcity offers a broad assortment of consumable products, general merchandise and seasonal items at select, fixed price points up to US$3.00 (or the equivalent in local currency) in El Salvador and Guatemala and up to the equivalent of US$4.00 in local currency in Colombia through its 240 conveniently-located stores.

About The Rossy Foundation

The Rossy Foundation is a Montreal-based private foundation that was established in 2004. Its mission is to contribute to civil society and to improve the lives of Canadians with a focus on cancer care, mental health, civic engagement, education and the arts. It is committed to supporting the vibrancy of Montreal and also funds charitable organizations across Canada and internationally within its areas of focus.

www.dollarama.com

Cision View original content:http://www.prnewswire.com/news-releases/sale-of-shares-by-dollarama-insiders-301191509.html

SOURCE Dollarama Inc.

Contango ORE, Inc. Announces Results of the Annual Meeting of Stockholders; Calendar Year 2021 Budget for Joint Venture Company

Contango ORE, Inc. Announces Results of the Annual Meeting of Stockholders; Calendar Year 2021 Budget for Joint Venture Company

HOUSTON–(BUSINESS WIRE)–
Contango ORE, Inc. (“CORE” or the “Company”) (OTCQB: CTGO) announced today that the Company held its annual meeting of stockholders on December 11, 2020 and the following directors were elected to serve until the 2021 annual meeting of stockholders:

Brad Juneau

Rick Van Nieuwenhuyse

Joseph S. Compofelice

Joseph G. Greenberg

Richard A. Shortz

The following proposals were also approved by the stockholders:

  1. The ratification of the appointment of Moss Adams LLP as the independent auditors of the Company for the fiscal year ending June 30, 2021;
  2. The approval of an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of its common stock from 30,000,000 shares to 45,000,000 shares;
  3. The approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers;
  4. The approval, on a non-binding advisory basis, of an annual advisory vote on the compensation of the Company’s named executive officers; and
  5. The grant of discretionary authority to the Chairman of the Annual Meeting to adjourn the Annual Meeting, if necessary to solicit additional proxies.

Additionally, the Company’s Board of Directors re-appointed the following officers of the Company:

Brad Juneau – Executive Chairman of the Board

Rick Van Nieuwenhuyse – President and Chief Executive Officer

Leah Gaines – Vice President, Chief Financial Officer, Chief Accounting Officer, Treasurer and Secretary

On December 10, 2020, the Management Committee of Peak Gold, LLC (“Peak Gold”), the Company’s joint venture with Kinross Gold Corporation (“Kinross”) approved a total budget of $18 million for calendar year 2021 to undertake in-fill drilling, engineering and environmental studies necessary to complete a Feasibility level study, additional exploration, community relations and ready the project for formal permitting. The Company’s proportionate share of the approved budget is approximately $5.4 million.

Rick Van Nieuwenhuyse, the Company’s President and CEO commented, “CORE’s stockholders have overwhelmingly supported the board and management as we chart a clear path to achieve commercial production at the Peak Gold project along with our partners at Kinross Gold and the Tetlin Alaska Native Tribe. We are completing an expected $3.6 million fourth quarter calendar year drill and environmental program at the Peak Gold site. We have also approved an $18 million Peak Gold budget (CORE’s share is $5.4 million) for calendar year 2021 to undertake in-fill drilling, engineering and environmental studies necessary to complete a Feasibility level study, additional exploration, community relations and ready the project for formal permitting. It is exciting to see the tangible progress being made to advance the Peak Gold resource.”

ABOUT CORE

CORE is a Houston-based company that engages in the exploration in Alaska for gold and associated minerals through a 30% interest in Peak Gold, LLC, which leases approximately 675,000 acres for exploration and development and through Contango Minerals Alaska, LLC, its wholly owned subsidiary which leases approximately 168,000 acres for exploration. Additional information can be found on our web page at www.contangoore.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements regarding CORE that are intended to be covered by the safe harbor “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995, based on CORE’s current expectations and includes statements regarding future results of operations, quality and nature of the asset base, the assumptions upon which estimates are based and other expectations, beliefs, plans, objectives, assumptions, strategies or statements about future events or performance (often, but not always, using words such as “expects”, “projects”, “anticipates”, “plans”, “estimates”, “potential”, “possible”, “probable”, or “intends”, or stating that certain actions, events or results “may”, “will”, “should”, or “could” be taken, occur or be achieved). Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties, which could cause actual results to differ materially from those, reflected in the statements. These risks include, but are not limited to: the risks of the exploration and the mining industry (for example, operational risks in exploring for, developing mineral reserves; risks and uncertainties involving geology; the speculative nature of the mining industry; the uncertainty of estimates and projections relating to future production, costs and expenses; the volatility of natural resources prices, including prices of gold and associated minerals; the existence and extent of commercially exploitable minerals in properties acquired by CORE or Peak Gold LLC; ability to realize the anticipated benefits of the recent transactions with an affiliate of Kinross; disruption from the transactions and transition of the Joint Venture Company’s management to an affiliate of Kinross, including as it relates to maintenance of business and operational relationships; potential delays or changes in plans with respect to exploration or development projects or capital expenditures; the interpretation of exploration results and the estimation of mineral resources; the loss of key employees or consultants; health, safety and environmental risks and risks related to weather and other natural disasters); uncertainties as to the availability and cost of financing; CORE’s inability to retain or maintain its relative ownership interest in the Joint Venture; inability to realize expected value from acquisitions; inability of our management team to execute its plans to meet its goals; the extent of disruptions caused by the COVID-19 outbreak; and the possibility that government policies may change, political developments may occur or governmental approvals may be delayed or withheld, including as a result of the recent presidential and congressional elections in the U.S. or the inability to obtain mining permits. Additional information on these and other factors which could affect CORE’s exploration program or financial results are included in CORE’s other reports on file with the U.S. Securities and Exchange Commission. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from the projections in the forward-looking statements. Forward-looking statements are based on the estimates and opinions of management at the time the statements are made. CORE does not assume any obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.

Contango ORE, Inc.

Rick Van Nieuwenhuyse

(713) 877-1311

www.contangoore.com

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Mining/Minerals Natural Resources

MEDIA:

Logo
Logo

Splunk (SPLK) Class Action Alert: Johnson Fistel Encourages Investors Suffering Losses to Contact Firm

PR Newswire

SAN DIEGO, Dec. 11, 2020 /PRNewswire/ — Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of shareholders of Splunk Inc. (NASDAQ: SPLK). The class action is on behalf of shareholders who purchased Splunk between October 21, 2020 and December 2, 20200, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff in this class action, you must move the Court no later than February 2, 2021.

[Click here to join this action]

The Complaint alleges that defendants throughout the Class Period made false and misleading statements and failed to disclose that: (1) Splunk was not closing deals with its largest customers in the third fiscal quarter of 2021; (2) Splunk was not hitting the financial targets it had previously announced; and (3) as a result of the foregoing, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Jim Baker ([email protected]) at 619-814-4471.  If emailing, please include a phone number. 

Additionally, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:

Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson Fistel, LLP
Jim Baker, 619-814-4471 
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/splunk-splk-class-action-alert-johnson-fistel-encourages-investors-suffering-losses-to-contact-firm-301191288.html

SOURCE Johnson Fistel, LLP

WeissLaw LLP Reminds GIX, JWS, TNAV, and WPX Shareholders About Its Ongoing Investigations

PR Newswire

NEW YORK, Dec. 11, 2020 /PRNewswire/ —


If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:


Joshua Rubin, Esq.

WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

GigCapital2, Inc. (NYSE: GIX)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GigCapital2, Inc. (NYSE: GIX) in connection with GIX’s merger with privately-held Cloudbreak Health, LLC (“Cloudbreak”).  Under the terms of the agreement, GIX will acquire Cloudbreak through a reverse merger that will result in Cloudbreak becoming a publicly-listed company.  If you own GIX shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/gix/  

Jaws Acquisition Corp. (NYSE: JWS)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Jaws Acquisition Corp. (NYSE: JWS) in connection with JWS’ merger with privately-held Cano Health, LLC (“Cano”).  Under the terms of the agreement, JWS will acquire Cano through a reverse merger that will result in Cano becoming a publicly-listed company.  If you own JWS shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/jws/ 

Telenav
, Inc. (NASDAQ: TNAV)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Telenav, Inc. (NASDAQ: TNAV) in connection with the proposed interested-party acquisition of the company by V99, Inc., a corporation led by TNAV’s President and CEO HP Jin.  TNAV shareholders will receive only $4.80 for each share of TNAV that they hold, which appears to significantly undervalue TNAV especially in light of the conflicts inherent in the transaction.  If you own TNAV shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/tnav/ 

WPX Energy, Inc. (NYSE: WPX)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of WPX Energy, Inc. (NYSE: WPX) in connection with the proposed acquisition of the company by Devon Energy Corporation (“DVN”).  Under the terms of the acquisition agreement, WPX shareholders will receive 0.5165 shares of DVN for each share of WPX common stock that they own, representing implied per-share merger consideration of $8.56 based upon DVN’s December 10, 2020 closing price of $16.57.  If you own WPX shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/wpx/  

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/weisslaw-llp-reminds-gix-jws-tnav-and-wpx-shareholders-about-its-ongoing-investigations-301191502.html

SOURCE WeissLaw LLP

GDRX Alert: Johnson Fistel Launches Investigation into GoodRx; Investors Suffering Losses Encouraged to Contact the Firm

PR Newswire

SAN DIEGO, Dec. 11, 2020 /PRNewswire/ –Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) for potential violations of federal securities laws.

On September 23, 2020, GoodRx sold about 34.6 million shares of stock in its initial public stock offering (the “IPO”) at $33.00 a share, raising approximately $1.1 billion in new capital. Post-IPO, GoodRx stock traded at a high of $64.22; on December 10, 2020, the stock closed at $38.92.

Specifically, Johnson Fistel’s investigation seeks to determine whether the Company’s filings with the U.S. Securities and Exchange Commission in connection with its September 2020 IPO contained untrue statements of material facts or omitted to state other facts necessary to make the statements made therein not misleading concerning the Company’s business, and operations.

If you have information that could assist in this investigation, or if you are a GoodRx shareholder and are interested in learning more about the investigation, please contact Jim Baker ([email protected]) at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:

Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson Fistel, LLP
Jim Baker, 619-814-4471
[email protected]

[Click here to join this action]

Cision View original content:http://www.prnewswire.com/news-releases/gdrx-alert-johnson-fistel-launches-investigation-into-goodrx-investors-suffering-losses-encouraged-to-contact-the-firm-301191287.html

SOURCE Johnson Fistel, LLP

(NKLA) Alert: Johnson Fistel Investigates Nikola Corporation; Did You Purchase Shares before May 8, 2020?

PR Newswire

SAN DIEGO, Dec. 11, 2020 /PRNewswire/ — Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Nikola Corporation (“Nikola or the “Company”) (NASDAQ: NKLA).

If you purchased shares in Nikola
or its predecessor VectoIQ
before May 8, 2020,
 and would like additional information, go to:
 [

click here to join this action],

 or contact Jim Baker (

[email protected]

) by email or phone at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [

click here to join this action]. There is no cost or obligation to you.

About

Johnson Fistel, LLP:


Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson Fistel, LLP
Jim Baker, 619-814-4471
[email protected]

[

click here to join this action].

Cision View original content:http://www.prnewswire.com/news-releases/nkla-alert-johnson-fistel-investigates-nikola-corporation-did-you-purchase-shares-before-may-8-2020-301191285.html

SOURCE Johnson Fistel, LLP

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of ZAGG Inc Buyout

WILMINGTON, Del., Dec. 11, 2020 (GLOBE NEWSWIRE) — Rigrodsky & Long, P.A. announces that it is investigating ZAGG Inc (“ZAGG”) (NASDAQ GS: ZAGG) regarding possible breaches of fiduciary duties and other violations of law related to ZAGG’s agreement to be acquired by a buyer group led by Evercel, Inc. Under the terms of the agreement, ZAGG’s shareholders will receive $4.50 in cash per share and an additional contingent amount of up to $0.25 in cash per share if certain conditions are met.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-zagg-inc.

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected].

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT:

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
[email protected]
https://rl-legal.com



Kraig Biocraft Laboratories Secures Bridge Funding and Files to Become Fully Reporting Company

ANN ARBOR, Mich., Dec. 11, 2020 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), announced today that it has secured $950,000 in bridge financing and simultaneously filed with the SEC to become a mandatory, fully reporting company. Today the Company filed a Form 8-A to become fully reporting issuer. This financing will also make a significant contribution to that effort.

“While being a voluntary filer, Kraig has been committed to meeting all SEC filing and reporting standards. Our election to now formalize these reporting responsibilities is evidence of our commitment to full operational transparency and growth,” said CEO and Founder, Kim Thompson. “The bridge financing will be used to continue scaling up our recombinant spider silk production and for other purposes related to the near term implementation of our business plan.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk based fiber technologies.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Except as required by law, the Company does not undertake any responsibility to revise or update any forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
[email protected]



Ziopharm Comments on Delay of WaterMill’s Stated Consent Deadline

Ziopharm Recommends Shareholders Return the


GREEN


Consent Revocation Card

BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, “WaterMill”) following the delay of the original December 11 deadline set by WaterMill for Ziopharm shareholders to deliver written consents in support of the Consent Solicitation. Ziopharm continues to strongly recommend shareholders sign and return the Company’s GREEN Consent Revocation Card.

The statement is as follows:

“We have been informed that WaterMill has requested to delay the voting deadline until December 15, a clear sign that it does not appear to have the level of shareholder support for its proposals it claimed to have. As has been the case since this process commenced in mid-October, Ziopharm’s Board and management team remain fully committed to acting in the best interest of shareholders and have relayed the Company’s willingness to reach an amicable resolution with WaterMill. It is our preference to resolve this matter amicably so we can continue to focus on our important progress toward developing therapies that could treat the millions of people globally diagnosed with a solid tumor each year.”

Information related to the Consent Solicitation can be found at www.ZiopharmForward.com.

About Ziopharm Oncology, Inc.

Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm’s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit www.ziopharm.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements regarding the business strategy, plans and objectives of Ziopharm management and expectations as to and beliefs about the Consent Solicitation initiated by WaterMill. Forward-looking statements include all statements that are not historical facts, and can be identified by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or similar expressions and the negatives of those terms. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Such risks and uncertainties include, among others, the impact and results of the Consent Solicitation and other activities by WaterMill and/or other investors, the risks and uncertainties disclosed in Ziopharm’s most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 as well as discussions of potential risks, uncertainties and other important factors in any subsequent filings by Ziopharm with the Securities and Exchange Commission (the “SEC”). All information in this press release is as of the date hereof, and Ziopharm undertakes no duty to update the information, except as required by law.

Important Additional Information and Where to Find It

Ziopharm has filed a definitive consent revocation statement (the “Consent Revocation Statement”) together with a GREEN consent revocation card with the SEC in connection with the Consent Solicitation. SHAREHOLDERS ARE URGED TO READ THE CONSENT REVOCATION STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT ZIOPHARM FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Shareholders will be able to obtain, free of charge, copies of the Consent Revocation Statement (including the GREEN consent revocation card), any amendments or supplements thereto and any other documents that Ziopharm files with the SEC from the SEC’s website (http://www.sec.gov) or from Ziopharm’s website (www.ziopharm.com) by clicking on “Investors” and then “SEC Filings.”

Investor Relations Contacts:

Adam D. Levy, PhD, MBA
EVP, Investor Relations and Corporate Communications
(508) 552-9255
[email protected]

Michael Verrechia
Morrow Sodali
(212) 300-2476
[email protected]

Media Relations Contacts:

Chris Kittredge, Andrew Cole and Zachary Tramonti
Sard Verbinnen & Co.
[email protected]

 



SHAREHOLDER ALERT: WeissLaw LLP Reminds ROCH, TOTA, and DMYD Shareholders About Its Ongoing Investigations

PR Newswire

NEW YORK, Dec. 11, 2020 /PRNewswire/ —


If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:


Joshua Rubin, Esq.

WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

Roth CH Acquisition I Co. (NASDAQ: ROCH)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Roth CH Acquisition I Co. (NASDAQ: ROCH) in connection with the company’s proposed merger with privately-held PureCycle Technologies LLC (“PureCycle”).  Under the terms of the agreement, ROCH will acquire PureCycle through a reverse merger that will result in PureCycle becoming a public company traded on the NASDAQ Capital Market.  If you own ROCH shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/news/roch/

Tottenham Acquisition I Limited
(NASDAQ: TOTA)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Tottenham Acquisition I Limited (NASDAQ: TOTA) in connection with the company’s proposed merger with privately-held clinical-stage biopharmaceutical company, Clene Nanomedicine, Inc. (“Clene”).  Under the terms of the agreement, TOTA will acquire Clene through a reverse merger that will result in Clene becoming a public company.  If you own TOTA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/tottenham-acquisition-i-limited/

dMY Technology Group, Inc. II (NYSE: DMYD)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of dMY Technology Group, Inc. II (NYSE: DMYD) in connection with the company’s proposed merger with Genius Sports Group Limited (“GSG”).  Under the terms of the agreement, DMYD will acquire GSG through a reverse merger that will result in GSG becoming a public company.  If you own DMYD shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/dmyd/

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-roch-tota-and-dmyd-shareholders-about-its-ongoing-investigations-301191459.html

SOURCE WeissLaw LLP